Type something and hit enter

ads here
On
advertise here

https://www.globenewswire.com/news-release/2021/11/23/2339698/0/en/ONCOTELIC-ANNOUNCES-POSITIVE-TOPLINE-DATA-FOR-OT-101-C001-COVID-STUDY.html

1)  Safety endpoints met. OT-101 as a TGF-β inhibitor was safe to administer to COVID-19 patients including severe/critical COVID-19 patients.

2) Efficacy signals were obtained. End of treatment (Day 7) mortality for the entire study population was 4.5% OT-101 versus 20% for placebo.

3)  Incidence of >96% viral load knockdown on End of Treatment (Day 7) was 89% for OT-101 versus 67% for placebo.

4)  Overall survival improved 3X for critical COVID-19 pts (4 days for placebo versus 14 days for OT-101, p < 0.0166).

“It is gratifying that the TGF-β concept that we put forward has now been validated,” said Dr. Vuong Trieu, CEO and Chairman of Oncotelic. “The data form the basis for further development of OT-101 as a viable treatment for severe respiratory viral infections, including flu and COVID-19. We thank the patients and investigators involved, especially Dr. Carbajal of Calle Mariscal Sucre, Chancay, Huaral, Lima, Peru, who drove the study to its conclusion.”



Submitted November 23, 2021 at 07:11AM by drvljanikqr https://ift.tt/3HPMdGg

Click to comment